In this issue of JAMA Ophthalmology, Hsu and coauthors1 evaluated whether there is a difference in retinal fluid using intravitreous injections with or without adjunctive topical dorzolamide-timolol drops among eyes with persistent fluid from neovascular age-related macular degeneration. The authors concluded that the study findings suggest that dorzolamide-timolol reduces macular edema compared with placebo. This conclusion was likely based on the P value of the primary outcome (P = .04) being less than the prespecified threshold for statistical significance (P < .05). However, what are the implications of drawing conclusions from P values alone?
Glassman AR. Are P Values Enough? JAMA Ophthalmol. 2020;138(5):567–568. doi:10.1001/jamaophthalmol.2020.0710
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.